Iovance Biotherapeutics, Inc.
IOVA
Rang in Aktien
#2912
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aktienkurs
$14.09
Marktkapitalisierung
$6.38B
Veränderung (1 Tag)
3.44%
Veränderung (1 Jahr)
546.27%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategorie
Healthcare
EPS für Iovance Biotherapeutics, Inc. (IOVA)
EPS zum June 2026 TTM: $-0.73
Laut den aktuellen Finanzberichten und dem Aktienkurs von Iovance Biotherapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-0.73. Am Ende des Jahres 2023 betrug das EPS $-1.89 ein Rückgang im Vergleich zu dem EPS von 2022, das $-2.49 betrug.
EPS-Verlauf von Iovance Biotherapeutics, Inc. von 2008 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.73 | -42.97% |
| 2024 | $-1.28 | -32.28% |
| 2023 | $-1.89 | -24.10% |
| 2022 | $-2.49 | 11.66% |
| 2021 | $-2.23 | 18.62% |
| 2020 | $-1.88 | 25.33% |
| 2019 | $-1.50 | 18.11% |
| 2018 | $-1.27 | -9.93% |
| 2017 | $-1.41 | 46.88% |
| 2016 | $-0.96 | 54.84% |
| 2015 | $-0.62 | 29.17% |
| 2014 | $-0.48 | -81.54% |
| 2013 | $-2.60 | -37.20% |
| 2012 | $-4.14 | -87.77% |
| 2011 | $-33.84 | 1,275.61% |
| 2010 | $-2.46 | 14,370.59% |
| 2009 | $-0.02 | -63.91% |
| 2008 | $-0.05 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -2,472.60% |
US
|
|
| $-7.98 | 993.15% |
US
|
|
| $-5.29 | 624.66% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,900.00% |
NL
|
